THE OFFICIAL NEWS SOURCE OF ACR CONVERGENCE 2022 • NOVEMBER 10-14
-
Plenary I highlights interplay between COVID-19 and autoimmune dysfunction
Plenary Session I focused on growing links between SARS-CoV-2 infection and autoimmune events that are more often seen in rheumatologic diseases. READ MORE
-
Plenary II: DOACs could be the better choice than warfarin for OA patients
A retrospective analysis of knee and hip replacements in patients with atrial fibrillation on anticoagulation therapy was one of the presentations during the Plenary II session during ACR Convergence 2020. READ MORE
-
Mavrilimumab reduces flare and increases sustained remission in giant cell arteritis, late-breaking abstract reports
The ACR Convergence 2020 Late-Breaking Abstracts session featured six presentations on cutting-edge science. READ MORE
-
Plenary III: Data shows belimumab improves SLE control, renal outcomes, steroid use
Results from the BLISS-LN trial was one of the highlights from the Plenary III session. READ MORE
-
Panelists review draft updated ACR guideline for RA management
A new ACR guideline for the management of rheumatoid arthritis (RA) has been drafted and is expected to be approved later this year and published by early spring 2021. READ MORE
-
Session explores COVID-19 impact on rheumatic disease populations
Members of the Global Rheumatology Alliance (GRA) COVID-19 Steering Committee presented data from the COVID-19 GRA Registry on the impact of the pandemic on the rheumatology community. READ MORE
-
New ACR leadership confirmed at 2020 Business Meeting
David Karp, MD, PhD, became the 84th ACR President. Additionally, Kenneth G. Saag, MD, MSc, became ACR President-Elect, and Deborah Dyett Desir, MD, was confirmed by the membership as the new ACR Secretary. READ MORE